Thu, Aug 21, 2014, 5:36 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

BSD Medical Corp. Message Board

bluechiptool 43 posts  |  Last Activity: 2 hours 21 minutes ago Member since: Aug 13, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • bluechiptool bluechiptool 2 hours 21 minutes ago Flag

    Johnson & Johnson medical devices and diagnostics company Depuy Synthes had 2013 sales of $28.5 billion.

    Sentiment: Strong Buy

  • bluechiptool bluechiptool 2 hours 55 minutes ago Flag

    Siemens Health Services, GE Health or Terumo

    Sentiment: Strong Buy

  • bluechiptool bluechiptool 3 hours ago Flag

    OKKKKKKKKKKKKKKKKKKKKKKKKKK shorty

    Sentiment: Strong Buy

  • BSD Medical's innovative MicroThermX Microwave Ablation System is being used to successfully treat at four cancer patients at hospitals in Italy. The treatments were conducted within a four-day period and were attended by numerous key Italian physicians. Med-Italia Biomedica (Med-Italia), one of the largest interventional radiology/oncology distributors in Italy, purchased the MicroThermX system and coordinated the delivery of the treatments.

    The four participating hospitals included some of Italy's leading hospitals: Ospedaliera Spedali Civili in Brescia, one of the largest hospitals in Northern Italy; Istituto Clinico Humanitas in Rozzano, a teaching center for the University of Milan’s International Medical School; Instituto Europeo Di Oncologia in Milano, a leading cancer treatment hospital and home to Umberto Veronesi, MD, one of Italy’s most respected cancer surgeons; and Ospedale di San Giovanni Battista in Torino, the oldest hospital in Torino and the largest hospital in Piedmont.

    Sentiment: Strong Buy

  • bluechiptool bluechiptool 6 hours ago Flag

    The other 9 it stopped growing. 100%Researchers are using high-energy waves similar to those used to make microwave popcorn to destroy inoperable lung tumors.
    In a preliminary study, the technique, called microwave ablation, eliminated lung tumors in 19 of 28 patients. Eight months later, none of the tumors had come back.
    Tumors shrank or stopped growing in the other nine patients, says study researcher Claudio Pusceddu, MD, a specialist in radiation and oncology at Oncological Hospital in Cagliari, Italy.
    During microwave ablation, radiologists place a thin microwave antenna directly into the tumor. An electromagnetic wave then agitates water molecules in the surrounding tumor tissue, producing friction and heat that eventually destroy the tumor.
    The procedure, which costs about $2,000, takes about an hour, and the patient is typically kept overnight in the hospital for observation.
    U.S. researchers say the technique certainly shows promise. But more patients have to be followed for far longer to see if they stay in remission, they say.
    The findings were presented here at the annual meeting of the Radiological Society of North America.
    A Visual Guide to Lung Cancer
    Microwave Ablation for Lung Cancer
    About 373,000 Americans are living with lung cancer, according to the American Cancer Society.
    Standard treatment options include surgery, chemotherapy, and radiation. Researchers are looking at a number of ways of destroying tumors with heat from radiofrequency waves or by freezing it, for example.
    It remains to be seen which of these newer techniques, if any, will keep cancer from coming back, says American Society of Clinical Oncology spokesman Gregory Masters, MD, a medical oncologist at the Helen F. Graham Cancer Center in Newark, Del.
    Masters tells WebMD that in one study, cancer stopped growing for a year or more in two-thirds of patients who underwent microwave ablation. LOOK ON WEBMD

    Sentiment: Strong Buy

  • Why is Michael Nobel on BSD Medicals Board of Directors?
    BSD MEDICAL CORP Director and holding 354,545 shares of stock?
    Profile
    Michael Nobel, Ph.D., has served as a director of BSD since January 1998. Dr. Nobel participated in the introduction of magnetic resonance imaging as European Vice President of Fonar Corp. He is founder and trustee of the Nobel Sustainable Trust Foundation and chairman of Nobel Charitable Trust Foundation (Asia). From 1991 to 2007, Dr. Nobel served as the Executive Chairman of the MRAB Group, a company providing diagnostic imaging services to Sweden. From August 2005 until June 2008, Dr. Nobel served as a director of WorldSpace Corp. He has also been a consultant to Unesco in Paris and the United Nations Social Affairs Division in Geneva. Today, Dr. Nobel is chairman or board member of several international companies in medical diagnostics, treatment and information systems. He is a guest professor at the Tokyo Institute of Technology in Japan.

    Sentiment: Strong Buy

  • bluechiptool bluechiptool 6 hours ago Flag

    Blow-hard!

    Sentiment: Strong Buy

  • bluechiptool bluechiptool 7 hours ago Flag

    HE is a young 52 years old and he is respected world-wide

    Sentiment: Strong Buy

  • Damian E. Dupuy, MD, was appointed a Director in April 2011. Dr. Dupuy has been a Professor of Diagnostic Imaging at the Warren Alpert Medical School of Brown University since 2005, and has served as Director, Tumor Ablation, at Rhode Island Hospital in Providence, RI since 2001. Dr. Dupuy, a fellow of the American College of Radiology, is a pioneer in the growing field of image guided tumor ablation, whereby various types of thermal devices destroy tumors by direct placement through the skin under image guidance. Dr. Dupuy is internationally known for his pioneering clinical work in treating cancer patients who suffer from tumors of the lung, liver, kidney, head and neck, pelvis, adrenal and skeleton. Dr. Dupuy has led two National Cancer Institute multi-center trials and currently is the Interventional Oncology Symposium Chair of the Radiological Society of North America. Dr. Dupuy, who is a graduate of the University of Massachusetts, Amherst, and the University of Massachusetts Medical School, has published widely on a variety of specialized medical issues and is the recipient of numerous post-graduate honors and awards, including an American College of Radiology Imaging Network Publications Merit Award in 2010. Dr. Dupuy's qualifications to serve on the Board include, among others, his extensive medical and business experience, his expert knowledge of image-guided tumor ablation and extensive clinical and research experience with microwave ablation devices and his experience having served as a director of the Company since April 2011.
    Source: BSD Medical Corp. on 12/30/2013

    Sentiment: Strong Buy

  • Reply to

    GE and BSD go back to 2009 and Duke!

    by bluechiptool Aug 20, 2014 2:57 PM
    bluechiptool bluechiptool Aug 20, 2014 3:48 PM Flag

    I read the studies and I believe GE wants the 2000 and the 500 both fits well with them.

    Sentiment: Strong Buy

  • This novel capability is applicable to the 915MHz operating frequency of the BSD-500 hyperthermia system.

    The company discovered through research that at 915MHz the characteristics of breast tumours 4 to 5cm in diameter (those typically treated with radiation and/or chemotherapy) selectively absorb microwave energy, while the microwaves largely pass through the other tissues of the breast. The discovery of this selective heating capability could be used in numerous ways for better delivery of hyperthermia in treating breast cancer.

    However, one of the novel applications is to use selective heating of breast tumours to release tiny heat-triggered capsules of chemotherapy drugs as they enter breast tumours through the blood stream, causing the capsules to burst inside the tumour, greatly multiplying the potency of the drug delivery.

    In this case the breast applicator would serve as the 'targeting system' to find and heat tumours and the heat-triggered drug capsules would become 'smart bombs' that release when heated as they enter the tumour.

    Duke University is already using BSD Medical's hyperthermia equipment to release chemotherapy drugs delivered in heat-triggered capsules, and one of the reasons for this new applicator development was to further support Duke's research already underway.

    This method of providing chemotherapy thus far has shown the ability to deliver 30 times more drug than would normally reach the tumour site with non-encapsulated drug.

    In addition to releasing the chemotherapy capsules, heat (hyperthermia) therapy makes the tumour's blood vessels porous so that the capsules can pass from the bloodstream into the tumour.

    Hyperthermia also increases oxygen levels within tumours, and oxygen is critical to the proper functioning of certain chemotherapy agents.

    Hyperthermia also amplifies the level of genetic damage that chemotherapy inflicts on cells by inhibiting enzymes that normally repair the damage.

    Breast cancer tumours that reach a diameter of 4cm or larger are commonly treated by radical breast removal.

    An important objective of this effort is to provide less invasive alternatives for treatment.

    Read more: http://www.prohealthservicezone.com/News_Detail_Bsd_medical_filess_a_patent_smart_non-invasive_chemotherapy_tool_417.asp#ixzz3AxejDyif

    Sentiment: Strong Buy

  • Reply to

    GE and BSD go back to 2009 and Duke!

    by bluechiptool Aug 20, 2014 2:57 PM
    bluechiptool bluechiptool Aug 20, 2014 3:07 PM Flag

    5 plus year of GE and BSD Medical teaming up on the BSD-200 MRI and think it is a safe bet GE is the one want to sale it!

    Sentiment: Strong Buy

  • Aug 4, 2009

    BSD hyperthermia system integrated with GE's MRI

    SALT LAKE CITY, 31 July 2009 - BSD Medical Corporation (NASDAQ:BSDM) announced today that the Company has completed integration of a BSD-2000/3D/MR Hyperthermia System with a GE Healthcare (GE) 1.5 Tesla magnetic resonance (MR) imaging system at the Duke Comprehensive Cancer Center at Duke University Medical Center. GE Healthcare is a division of the General Electric Company. This is the first installation in the United States of the BSD-2000/3D/MR and the first integration of a BSD-2000/3D/MR system with a GE MR system. The integration and installation was a joint effort between BSD Medical, Duke University, and GE Healthcare engineers, physicists, and physicians.

    The BSD-2000 system, which was invented by BSD Medical, delivers energy that can be electronically focused to target the 3-dimensional shape, size, and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000/3D/MR system integrates a BSD-2000/3D Hyperthermia System with an MR system. The integrated system was designed to deliver targeted hyperthermia therapy while simultaneously providing non-invasive imaging of the diseased tissue as well as the surrounding healthy tissue. Duke University is a world leader in the development of non-invasive imaging techniques for hyperthermia using MR imaging.

    About Duke University Medical Center
    Duke University Medical Center is one of 40 centers in the US that has been designated by the National Cancer Institute (NCI) as a "comprehensive cancer center". Duke is known for its cutting-edge research. The Duke Comprehensive Cancer Center is ranked as one of the top 10 cancer hospitals in the country, according to U.S. News & World Report's "America's Best Hospitals" survey.

    About BSD Medical Corporation
    BSD Medical's product line includes systems that have been strategically designed to offer a range of thermal treatment locations and indications. BSD Medical is the leading developer of hyperthermia systems. The BSD-2000 Hyperthermia System is currently restricted to investigational use in the United States. For further information visit BSD Medical's website at www.bsdmedical.com

    Sentiment: Strong Buy

  • Summary of "Radiofrequency Ablation in the Treatment of Breast Cancer Liver Metastases."
    Minimally invasive, image-guided thermal ablation is gaining acceptance for the treatment of solid tumour deposits and its use is increasing. This overview discusses one method of thermal ablation in one palliative setting; the local control of breast cancer liver metastases (BCLM) using radiofrequency ablation. Breast cancer is common and over half of all women diagnosed with metastatic disease develop BCLM. The mainstay of therapy remains chemotherapy and supportive care, which may prolong survival to a median of 18-24 months. Despite breast cancer being considered a systemic disease, surgical series of metastectomy for BCLM have shown a survival advantage. Despite this, surgery for BCLM is rarely practiced due to the associated morbidity for a relatively meagre survival benefit. Similarly, radiofrequency ablation has been used for local control of BCLM; the reported series show a median survival of between 30 and 60 months, with no treatment-related deaths and only three serious treatment-related adverse events in 164 patients reported. Despite this, scepticism remains over the efficacy of BCLM ablation due to the heterogeneity of patient inclusion and selective nature of reporting. Randomised trials are needed to formulate robust evidence-based recommendations and direct the necessary allocation of health care resources. Whether or not local ablative treatment of BCLM conveys a survival advantage is an important consideration. However, in this non-curative setting, it is essential that other outcome measures are carefully evaluated in conjunction with survival, including symptoms (local and constitutional), quality of life and psychological morbidity. To these ends, a randomised, multicentre trial to assess best medical therapy alone versus best medical therapy plus radiofrequency ablation in patients presenting with newly diagnosed BCLM with or without the presence of stable extra-hepatic disease will shortly be underway

    Sentiment: Strong Buy

  • bluechiptool bluechiptool Aug 19, 2014 11:57 AM Flag

    Team BSD Medical with JNJ and what will the price be? http://sierraworldequityreview.blogspot.com/2014/08/down-to-businessjohnson-johnson-jnj.html

    Sentiment: Strong Buy

  • bluechiptool bluechiptool Aug 19, 2014 11:53 AM Flag

    Come on shortests sell me some more!

    Sentiment: Strong Buy

  • Researchers are using high-energy waves similar to those used to make microwave popcorn to destroy inoperable lung tumors.
    In a preliminary study, the technique, called microwave ablation, eliminated lung tumors in 19 of 28 patients. Eight months later, none of the tumors had come back.
    Tumors shrank or stopped growing in the other nine patients, says study researcher Claudio Pusceddu, MD, a specialist in radiation and oncology at Oncological Hospital in Cagliari, Italy.
    During microwave ablation, radiologists place a thin microwave antenna directly into the tumor. An electromagnetic wave then agitates water molecules in the surrounding tumor tissue, producing friction and heat that eventually destroy the tumor.
    The procedure, which costs about $2,000, takes about an hour, and the patient is typically kept overnight in the hospital for observation.
    U.S. researchers say the technique certainly shows promise. But more patients have to be followed for far longer to see if they stay in remission, they say.
    The findings were presented here at the annual meeting of the Radiological Society of North America.

    Sentiment: Strong Buy

  • bluechiptool bluechiptool Aug 19, 2014 6:29 AM Flag

    http://www.terumo-europe.com/endovascular/products/microthermx-microwave-ablation-system.php

    Sentiment: Strong Buy

  • Brochure from Terumo
    MicroThermX - Microwave Ablation System
    The MicroThermX microwave ablation system consists of a generator and pump attached to a mobile cart or tabletop stand and SynchroWave antennas with cooling circuit.
    The MicroThermX microwave ablation system delivers microwave energy for coagulation (ablation) of soft tissue. The SynchroWave antennas may be used in open surgical as well as percutaneous ablation procedures. The synchronous wave alignment technology allows non-parallel placement and avoid skipping when using multiple antennas.
    Make it Simple
     Easy to set up
     Small and light generator able to plug up to 3 antennas
     Allows flexibility in antenna placement
     No risk of skin burn
    Be More Powerful
     Microwave allows faster treatments than Radiofrequency ablation (RFA)
     Bigger necrosis volume than RFA
    Act Safer
    • Better than RFA because it is not affected by heat sink effect (p

    Sentiment: Strong Buy

BSDM
0.685+0.005(+0.74%)Aug 21 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.